Initial Phase 1 Trial Report Shows Acceptable Safety, Early Efficacy Signals for T-Cell Receptor...
NT-175, a T-cell receptor T-cell therapy targeting the TP53 tumor suppressor gene, shows safety, tolerability, and early efficacy signals in patients with solid tumors, including pancreatic cancer,...
dailynews.ascopubs.org